Brief: Coeptis Therapeutics Anticipates Receiving Top Line Data For DVX201 Trial In 1Q24
14/09/2023 12:49
Sept 14 (Reuters) - Coeptis Therapeutics Holdings Inc
COEP.O :
* COEPTIS THERAPEUTICS PROVIDES SAFETY AND DOSING UPDATE
FROM
PHASE 1 TRIALS INVESTIGATING DVX201 IN RELAPSED/REFRACTORY AML
OR HIGH RISK MDS AND HOSPITALIZED COVID-19 INFECTION
* COEPTIS THERAPEUTICS HOLDINGS INC - ANTICIPATE RECEIVING
TOP
LINE DATA FOR THIS TRIAL IN 1Q24
* COEPTIS THERAPEUTICS HOLDINGS INC - DVX201 WAS TOLERATED
AT ALL
DOSING LEVELS
Source text for Eikon: ID:nPn46fGFQa
Further company coverage: COEP.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Z Squared (Delaware)
See all newsBrief: Z Squared Inc. Signs Definitive Agreement To Acquire 100% Of Paradox Data And Its Union County Campus
Brief: Z Squared, Inc. To Acquire Majority Interest In Paradox Data And Its Union County Campus, A Next-Generation Data Center Development Targeting Up To 150 MW Of Firm Power
Brief: Z Squared, Inc. Enters $50 Million Committed Equity Forward Purchase Agreement To Support Ai Infrastructure Buildout
Brief: Z Squared Appoints Jon Najarian, Pete Najarian, Marc Lopresti And Jay Zapata To Newly Formed Advisory Board
Brief: Z Squared Announces Executive Leadership Appointments To Advance Ai Infrastructure Strategy